Skip to main content
Bio-Gate AG logo

Bio-Gate AG — Investor Relations & Filings

Ticker · BIG1 ISIN · DE000BGAG981 LEI · 391200G5LKTIOTZOXP90 F Manufacturing
Open in API
Filings indexed 242 across all filing types
Latest filing 2021-02-08 Director's Dealing
Country DE Germany
Listing F BIG1

About Bio-Gate AG

https://www.bio-gate.de/en/

Bio-Gate AG is a provider of innovative technologies and customized solutions for health and hygiene, specializing in antimicrobial and antiviral strategies. The company enhances materials and products by incorporating its unique silver-based technologies, such as MicroSilver BG™. Key applications are concentrated in the medical technology sector, including the coating of medical implants and wound dressings to prevent infections. The company's technologies are also utilized in derma-cosmetics and veterinary care products. Furthermore, Bio-Gate provides solutions for industrial and consumer goods, imparting antimicrobial properties to items like paints, coatings, plastics, and textiles.

Recent filings

Filing Released Lang Actions
DGAP-DD: Bio-Gate AG deutsch
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains structured information detailing a transaction ('Geschäfte') involving a person in a management function ('Personen, die Führungsaufgaben wahrnehmen')—specifically a member of the Supervisory Board ('Aufsichtsrat')—and the company's shares. The German header 'DGAP-DD: Bio-Gate AG deutsch' further confirms this is a Director's Dealing notification (DD). This directly corresponds to the definition for Director's Dealing (DIRS).
2021-02-08 German
DGAP-DD: Bio-Gate AG deutsch
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains German text equivalent to 'Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen' (Notification and public disclosure of transactions by persons discharging managerial responsibilities). Section 1 identifies the person (Marc Lloret-Grau), Section 2 identifies the position (Vorstand/Executive Board member), and Section 4 details the transaction (Acquisition of shares as part of an employee participation program). This directly corresponds to the definition of Director's Dealing.
2021-02-08 German
DGAP-DD: Bio-Gate AG deutsch
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains the German equivalent header 'DGAP-DD: Bio-Gate AG deutsch' followed by 'Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen' (Notification and public disclosure of transactions by persons discharging managerial responsibilities). Section 4 details the transaction type, specifically the acquisition of shares by a board member (Vorstand) named Thomas Konradt. This directly corresponds to the definition of Director's Dealing.
2021-02-08 German
Jahresabschluss zum Geschäftsjahr vom 01.01.2019 bis zum 31.12.2019
Audit Report / Information Classification · 98% confidence The document is a 'Jahresabschluss' (Annual Financial Statement) for Bio-Gate AG for the fiscal year 2019. It contains a balance sheet (Bilanz), profit and loss statement (Gewinn- und Verlustrechnung), asset development schedule (Entwicklung des Anlagevermögens), and notes (Anhang). This constitutes the core components of an annual report under German commercial law (HGB). Although it is not a full glossy annual report with management commentary (Lagebericht), it is the primary financial reporting document for the year, which aligns with the 10-K category in the provided schema. FY 2019
2021-01-27 German
Bio-Gate AG: Bio-Gate AG schliet Barkapitalerhohung ab
Capital/Financing Update Classification · 98% confidence The document is an 'Ad-hoc-Mitteilung' (Ad-hoc announcement) dated January 26, 2021, explicitly referencing Article 17 of the EU Market Abuse Regulation (MAR). The content details the successful completion of a 'Barkapitalerhöhung' (cash capital increase) and the issuance of new shares, resulting in an increase in the share capital. This directly relates to changes in the company's capital structure and fundraising activities. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP). The document is short and serves as an announcement, not the full regulatory filing itself.
2021-01-26 German
Bio-Gate AG: Bio-Gate AG beschliet Barkapitalerhohung
Capital/Financing Update Classification · 99% confidence The document is an 'Ad-hoc-Mitteilung' (Ad-hoc announcement) dated January 21, 2021, explicitly stating that Bio-Gate AG resolved a cash capital increase ('Barkapitalerhöhung') through a private placement, excluding pre-emptive rights. This action directly relates to changes in the company's capital structure and fundraising activities. This aligns perfectly with the definition for Capital/Financing Update (CAP). The document is short and serves as an immediate regulatory disclosure regarding a financing event, not a comprehensive report.
2021-01-21 German

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.